EC
LXRX icon

EntryPoint Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

EntryPoint Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,498
Closed -$75.7K – 886
2026
Q1 		$75.7K Buy
48,498
+14,880
+44% +$21.6K 0.02% 715
2025
Q4 		$38.7K Buy
+33,618
New +$46.2K 0.02% 633
2024
Q1 		– Sell
-323,968
Closed -$496K – 1615
2023
Q4 		$496K Buy
+323,968
New +$385K 0.48% 6

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EntryPoint Capital's LXRX Position: Q2 2026 in Review

EntryPoint Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 48,498 shares — an estimated $75.7K sold.

EntryPoint Capital first reported a position in LXRX in Q4 2023 and held it in 3 quarters. The position peaked at $496K in Q4 2023. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • EntryPoint Capital reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 48,498 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $75.7K.
  • EntryPoint Capital first reported a position in Lexicon Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Lexicon Pharmaceuticals position peaked at $496K in Q4 2023.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.